Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the ever-shifting DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune system cells rearrange their DNA constantly in response to shifting threats in the environment. Sometimes the immune system malfunctions and begins attacking healthy tissues (e.g., autoimmune diseases) or certain immune system cells start proliferating out of control (cancer).
By digging into the immune cell sequences, Adaptive is creating a map of human immune system responses to threats. Armed with this information, Adaptive aims to develop blood tests that alert doctors when people are fighting specific diseases. Eventually, Adaptive wants to create a universal blood test that detects any disease a body might be fighting. Although such an all-encompassing test may be 10 years away, intermediate tests will come much sooner, according to CEO Chad Robins.
Adaptive was founded in 2009 by Chad Robins, Christopher Carlson, and Harlan Robins and is based in Seattle, Washington. The company has raised capital from investors such as Microsoft, Matrix Capital Management, Tiger Management and Viking Global Investors.
Overview of Adaptive Biotechnologies:
Source: WBBA TV
*Based on Preferred Stock Price, Adaptive Biotechnologies does not have a stock symbol since it is currently private and is yet to have an IPO.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Adaptive Biotechnologies or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.